The activity of 2'-benzoyloxycinnamaldehyde against drug-resistant cancer cell lines

J Chemother. 2007 Aug;19(4):428-37. doi: 10.1179/joc.2007.19.4.428.

Abstract

This study investigated the inhibitory effects of 2'-benzoyloxycinnamaldehyde (BCA) on cancer cells, including various drug-resistant cancer cell lines. To observe this activity, the anticancer drug-resistant cell lines were established by continuously exposing the parental cells to 5-fluorouracil (5-FU) and cyclophosphamide (CDDP), and examining the cells with the MTT assay and flow cytometric analysis. The BCA treatment produced similar growth inhibitory effects and apoptotic cell death on the drug-resistant cancer cells as their parental cells. The activation of the p38-mitogen activated protein kinase, an increased level of reactive oxygen species (ROS) generation and downregulation of Bcl-2 were observed in both the drug resistant and non-drug resistant cell lines. The GSH treatment effectively inhibited BCA-induced apoptosis by blocking ROS generation, suggesting that ROS is a major regulator in BCA-induced apoptotic cell death. These results suggest that BCA can be a useful drug candidate for treating drug-resistant cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrolein / analogs & derivatives*
  • Acrolein / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Apoptosis*
  • Benzoates / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Drug Resistance, Neoplasm*
  • Flow Cytometry
  • Humans
  • Neoplasms / metabolism*
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Reactive Oxygen Species / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • 2'-benzoyloxycinnamaldehyde
  • Antineoplastic Agents
  • Benzoates
  • Proto-Oncogene Proteins c-bcl-2
  • Reactive Oxygen Species
  • Acrolein
  • p38 Mitogen-Activated Protein Kinases